Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes.

ABSTRACT:

Importance

Concerns have been raised that glucagon-like peptide-1 receptor agonists (GLP-1RA) may increase the risk of pancreatic cancer.

Objective

To investigate the association of GLP-1RA treatment with pancreatic cancer incidence over 9 years of follow-up.

Design, setting, and participants

In this population-based historical cohort study, adult patients (aged 21 to 89 years) with type 2 diabetes insured by Clalit Healthcare Services, the largest state-mandated health organization in Israel, were followed up from 2009, when GLP-1RA became available in Israel, until pancreatic cancer diagnosis, death, reaching age 90 years, or end of follow-up (December 2017). Data were analyzed from June 2022 to November 2023.

Exposures

Treatment with GLP-1RA was compared wit

SUBMITTER: Dankner R 

PROVIDER: S-EPMC10767614 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature